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Introduction: Metabolic syndrome (MS) is associated with several cancers, but it is not clear whether MS affects the
prognosis of tongue squamous cell carcinoma (TSCC). This study aimed to evaluate the prognostic value of MS in
TSCC.
Methods: Clinical data from 252 patients with TSCC who were initially treated at the Sun Yat-sen University Cancer
Center between April 1998 and June 2011 were collected, and the associations between MS and clinicopathologic
factors were retrospectively analyzed. Prognostic outcomes were examined by Kaplan-Meier analysis and Cox
regression analysis.
Results: Of the 252 patients, 48 were diagnosed with MS. MS was associated with early N category in TSCC
(P < 0.001). The patients with MS showed longer survival than those without MS (P = 0.028). MS was an
independent prognostic factor for patients with TSCC.
Conclusions: MS is associated with early N category in TSCC. It is an independent prognostic factor for better
survival in patients with TSCC.
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Oral squamous cell carcinoma (OSCC) is a common
malignant tumor worldwide. OSCC accounts for over
90% of all oral cancers [1], and the most common loca-
tion for this disease is the tongue [2]. Tongue squamous
cell carcinoma (TSCC) is especially prevalent in low-
income communities in North France, East Europe,
South America, and Southeast Asia, and 90% of patients
with TSCC are over 45 years old [3]. TSCC seriously af-
fects quality of life of the patients and carries a poor
prognosis, with a 5-year overall survival (OS) rate of
56% [4].
Metabolic syndrome (MS) is a cluster of metabolic ab-
normalities. The pathophysiologic basis of MS is insulin* Correspondence: yangak@sysucc.org.cn
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unless otherwise stated.resistance [5]. The diagnosis criteria for MS include cen-
tral obesity, hyperglycemia, hypertriglyceridemia, hyper-
tension, and low serum concentration of high-density
lipoprotein (HDL) [6]. MS is related to several cancers,
including breast cancer, prostate cancer, and gastric can-
cer. MS and its components are associated with worse
survival in breast cancer [7] and prostate cancer [8], but
better survival for gastric cancer [9]. Obesity was re-
ported to be an adverse independent prognostic factor
for early-stage TSCC [10]. However, there is little infor-
mation regarding the association between MS and TSCC
or the impact of MS on TSCC patient survival. In this
study, we tried to analyze whether the status of MS be-
fore treatment have any impact on the OS in patients
with TSCC.Methods
Patient selection
A total of 252 patients diagnosed with TSCC who were
initially treated at the Sun Yat-sen University Canceris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Association between MS and clinicopathologic
characteristics of patients with TSCC






≥52 134 (53) 28 (58) 106 (52)
<52 118 (47) 20 (42) 98 (48)
Sex 0.273
Male 145 (58) 31 (65) 114 (56)
Female 107 (42) 17 (35) 90 (44)
T category 0.524
T1/T2 222 (88) 41 (85) 181 (89)
T3/T4 30 (12) 7 (15) 23 (11)
N category <0.001
N0 130 (52) 36 (75) 94 (46)
N+ 122 (48) 12 (25) 110 (54)
Pathologic grade 0.598
Well differentiated 184 (73) 33 (69) 151 (74)
Moderately differentiated 58 (23) 12 (25) 46 (23)
Poorly differentiated 10 (4) 3 (6) 7 (3)
Treatment 0.639
Surgery alone 193 (77) 38 (79) 155 (76)
Multimodality therapy 59 (23) 10 (21) 49 (24)
Tumor location 0.653
Lateral margin of the
tongue
185 (73) 34 (71) 151 (74)
Other locationsa 67 (27) 14 (29) 53 (26)
Total 252 48 204
MS, metabolic syndrome; TSCC, tongue squamous cell carcinoma. aOther
locations here include the apex linguae, dorsum, and ventrum of the tongue.
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in this study, including 145 males (58%) and 107 females
(42%). Subject ages ranged from 20 to 89 years, with a
median age of 52 years. None of these patients had dis-
tant metastasis before treatment. All patients underwent
surgery; 59 (23%) underwent multimodality therapy in-
cluding surgery. Surgical margins were tumor-free for all
patients. The data regarding MS and its components
were recorded before treatment. The OS was defined as
the duration from the date of initial treatment to the
date of death or the last follow-up (July 2014). This
study followed the Declaration of Helsinki for medical
protocol and ethics. Study approval was obtained from
independent ethics committees at Cancer Center of Sun
Yat-Sen University.
Diagnosis criteria of MS
According to the National Cholesterol Education Program’s
Adult Treatment Panel III, our diagnosis criteria of MS
included (1) fasting plasma glucose (GLU) ≥6.1 mmol/L
or a diagnosis of diabetes; (2) abdominal obesity, with a
body mass index (BMI) ≥25 kg/m2; (3) triglycerides
(TG) ≥1.7 mmol/L; (4) high-density lipoprotein
(HDL) ≤1.04 mmol/L for males and ≤1.3 mmol/L for
females; and (5) hypertension, with the systolic blood
pressure (BP) ≥130/80 mmHg. Meeting 3 or more of
the criteria was necessary for diagnosis [9].
Statistical analyses
The chi-square test was performed to analyze the rela-
tionship between MS and clinicopathologic factors of
TSCC. Kaplan-Meier and log-rank tests were used for
survival analysis. Multivariate Cox regression analysis
was performed for significant variables identified by
using univariate analysis. SPSS 16.0 software was used
for all analyses. A P value of <0.05 was considered statis-
tically significant.
Results
Association between MS and clinicopathologic
characteristics of TSCC
The clinicopathologic characteristics of 252 patients are
shown in Table 1. Of these patients, 48 (19.1%) were diag-
nosed with MS. MS was associated with early N category
(P < 0.001). However, there was no association between
MS and age, gender, T stage, pathologic grade, treatment
strategy, or tumor location.
Relationship between MS and survival of TSCC patients
At the time of the last follow-up, 184 patients (73.0%)
were alive, and 68 (27.0%) died of cancer-related dis-
eases. Figure 1 demonstrates that the patients with MS
had better OS than those without MS (P = 0.028). The
Cox proportional hazards model was used to verifywhether MS and other variables were independent prog-
nostic factors for TSCC patients. The univariate analysis
results showed that MS, sex, age, T category, N category,
pathologic grade, and treatment strategy were associated
with OS. Multivariate Cox regression analysis revealed
that MS, age, T category, N category, pathologic grade,
and treatment strategy were independent prognostic fac-
tors for patients with TSCC (Table 2).
Discussion
Our study demonstrated that MS was associated with
early N category in TSCC. In addition, MS was an inde-
pendent prognostic factor for better survival in patients
with TSCC.
This study first reported the association of MS with
early N category in TSCC. Previous reports demon-
strated that MS was associated with better differenti-
ation in gastric cancer cells [9], whereas others indicated
that MS or its components were associated with a more
Figure 1 Overall survival curves for patients with tongue
squamous cell carcinoma (TSCC) according to the status of
metabolic syndrome (MS). Kaplan-Meier analysis results indicate
that patients with MS have better overall survival than those without
MS (P = 0.028).
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cer [11,12]; the influence of MS on breast cancer re-
mains controversial [13,14]. The mechanism by which
MS influences N category is not well understood. Insulin
receptor and insulin-like growth factor 1 (IGF-1) are
expressed in most cancer cells, and IGF-1 can stimulate
invasion and proliferation of cervical cancer cells [15].
The patients with diabetes had low concentrations of
IGF-1 [16]. Moreover, the insulin receptor-activating sig-
naling pathways may offer protection from invasion and
metastasis of cancer cells [17,18]; however, the mechan-
ism remains unclear and requires further investigation.
In addition, underweight patients in China were associ-
ated with lower income and education, and they were
less likely to receive the correct treatment when diag-
nosed with an early-stage disease. The TNM classifica-
tion significantly affects tongue cancer prognosis; the
earlier the classification, the better the prognosis. In our
study, T category and N category were independent
prognostic factors for patients with TSCC. Liu et al. [19]
reported that the 5-year OS rates for patients with stages
I, II, III, and IV oral cancers were 79.8%, 68.2%, 57.2%,
and 50.4%, respectively. Thus, it is critical to diagnose
tongue cancer in early stages [3]. In addition, the patho-
logic grade significantly affects prognosis of the patients.
The patients who underwent multimodality therapy in
our study usually had late-stage disease, which leaded to
worse prognosis of these patients.
The impact of MS on cancer patient prognosis, includ-
ing cervical cancer, remains controversial. For example,
MS predicts poor survival in patients with prostatecancer and breast cancer [7,8], whereas Wei et al. [9] re-
ported that old patients with early-stage gastric cancer
and MS had a better prognosis. In patients with early-
stage colon cancer, diabetes and hypertension predicted
poor survival, but dyslipidemia predicted good survival
[20,21]. Another study reported increased odds of MS
among American women with a history of cervical can-
cer, but no association was observed between the single
component of MS and cervical cancer [22]. Several
reports suggested that leanness might be associated with
poor outcome for patients with cervical cancer [19,23-26].
However, obesity was considered an independent pre-
dictor of increased risk of death in patients with early-
stage tongue cancer [10]. However, patients in these
studies had various tumor sites and different pathologic
diagnoses. In addition, some of these studies were lim-
ited by small sample sizes. Our study found that MS
was associated with better prognosis in patients with
TSCC. Malnutrition is common in patients with head
and neck cancer, especially in oral tongue cancer, which
seriously affects the patient’s nutritional status, so
weight loss before treatment was associated with poor
prognosis. In addition, patients without MS are more
likely to suffer from nutritional deficiency, which may
lead to poor prognosis. Good nutritional status could
improve survival by strengthening immunity and pro-
viding high tolerance for lengthy therapeutic periods. A
retrospective research of oral cavity cancer and oropha-
ryngeal cancer showed that weight loss was a strong
predictor of death [19,24,26]. Another study also re-
ported poor survival in oral cancer patients with a BMI
< 22.8 kg/m2 before surgery [19].
Several individual components of MS have been recog-
nized as carcinogenic. However, our research did not
identify any significant influence of MS components on
TSCC prognosis. This result was similar to those of pre-
vious studies [9,22]. Epidemiologic studies indicated that
clustering MS components increased the carcinogenic
effect on colorectal cancer development and mortality
compared with individual factors [27,28]. Our findings
align with this theory of synergism among MS compo-
nents, as none of the individual MS components was as-
sociated with TSCC, but when clustering at least 3
components, this association became significant and
remained significant when adjusting for other risk fac-
tors for TSCC. Further investigations are needed to bet-
ter understand the effects of MS and its components on
survival in TSCC patients.
The molecular and cellular mechanisms by which
MS affects cancer patient survival are very complicated.
Smith et al. [29] reported that IGF-1 is a potential
pathway linking the environment with cancer. High levels
of IGF-1 increases the risk of cancer and aggressiveness
of malignancies. Cowey et al. [30] reported that TG
Table 2 Univariate and multivariate Cox regression analyses for overall survival in patients with TSCC
Variable Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Sexa 0.591 (0.356–0.984) 0.043 0.681 (0.398–1.166) 0.162
Age (years)
<52 Ref Ref
≥52 1.823 (1.100–3.020) 0.020 2.149 (1.279–3.614) 0.004
Tumor locationb 1.032 (0.607–1.754) 0.908
Pathologic grade
Well differentiated Ref Ref
Moderately differentiated 2.483 (1.475–4.183) 0.001 2.417 (1.417–4.124) 0.001
Poorly differentiated 4.728 (2.101–10.639) <0.001 2.726 (1.172–6.336) 0.020
T category
T1/T2 Ref Ref
T3/T4 3.575 (2.054–6.223) <0.001 2.007 (1.091–3.691) 0.025
N category
N0 Ref Ref
N+ 4.846 (2.725–8.618) <0.001 3.408 (1.873–6.202) <0.001
Treatment c 3.963 (2.451–6.407) <0.001 2.559 (1.492–4.392) 0.001
MS
With MS Ref Ref
Without MS 2.342 (1.070–5.125) 0.033 2.518 (1.126–5.631) 0.024
One component meets the criteria of MS
BMI 0.692 (0.330–1.448) 0.328
GLU 0.938 (0.491–1.792) 0.846
BP 0.745 (0.455–1.221) 0.243
TG 0.695 (0.391–1.235) 0.215
HDL 0.818 (0.491–1.361) 0.439
aMale versus female; bthe margo lateralis linguae versus other locations (the apex linguae, dorsum, and ventrum of the tongue); csurgery alone versus
multimodality therapy. TSCC, tongue squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; Ref, reference; MS, metabolic syndrome; BMI, body mass
index; GLU, fasting plasma glucose; BP, blood pressure; TG, triglycerides; HDL, high-density lipoprotein.
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apoptotic activity due to the generation of reactive oxygen
species (ROS) and oxidative stress, which cause DNA
damage. Obesity is linked with higher incidence and mor-
tality of several cancers, but there are still some opposing
opinions [10,19,23,24,26]. Levels of adipokine, leptin, and
adiponectin in obesity can affect several signal transduc-
tion pathways involved in cell survival [31], and Shin et al.
[32] reported that the adiponectin receptor is related to
gastric cancer development, progression, and poor sur-
vival. BMI influences cancers by releasing several in-
flammatory mediators, such as tumor necrosis factor
alpha, interleukin-6, and prostaglandin E2 [33]. A pre-
vious study reported an association between cervical
cancer and low HDL levels [22].
Our study had some limitations. First, it was a retro-
spective study. Second, this study did not include disease-
free survival due to limited clinical data. Third, we did notknow the exact time of the occurrence of MS, which may
lead to an overestimation of the associations.
Conclusions
In conclusion, this study first demonstrated that MS is as-
sociated with early N category and predicts good prognosis
in patients with TSCC. Understanding the underlie molecu-
lar and cellular mechanisms may provide clues to prevent
cancer development. Similarly, therapeutic interventions
targeting these molecular mechanisms might manifest a
positive perspective for the treatment of TSCC. In addition,
our results indicate that good nutritional status may improve
survival in patients withTSCC.
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